Phase 2Recruiting

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

VATCH (Vascular Anomaly Analysis for Therapy Choice): Phase II Study of Alpelisib Treatment in Subjects With TIE2/PIK3CA Pathway Driven Vascular Anomalies

Sponsor
Children's Hospital of Philadelphia (Academic or other)
Enrollment
61 planned
Conditions
Vascular Anomalies; Vascular Anomaly; TIE2/PIK3CA Pathway Driven Vascular Anomalies
Interventions
alpelisib (BYL719)
Ages
children, adults
Registry
NCT07543822

Full record on ClinicalTrials.gov

From the registry

The study will enroll participants 2 months of age up to 30 years of age. The purpose of this study is to assess the effectiveness and safety of Alpelisib (the "Study Drug") in patients with PIK3CA/TIE-2/TEK pathway driven vascular anomalies (VA). Alpelisib has been approved by the U.S. Food and Drug Administration (FDA) for treating adults and children with certain types of breast cancer. Its use in this study is considered experimental because FDA has not approved the study drug for treating people with VAs. Study participation will last for up to 3 years and will involve regular study visits to Children's Hospital of Philadelphia (CHOP)'s Philadelphia Campus. Participants will need to take the study drug Alpelisib for at least 2 years, or up to 3 years in total if there is a positive response. Participating in this research means you will attend up to 16 clinic visits for the purposes of the study. Most visits will take approximately 30 minutes, but some visits will take approximately 2 hours, because you will be asked to complete questionnaires about your experience.…

Primary outcomes

  • Percentage of subjects with a Substantial Response or Intermediate Response to Alpelisib using an Individualized Response Criteria
  • Relative size of target lesion(s) as determined by radiologic assessment
  • Quality of life as evaluated by PROMIS Patient Reported Outcome (PRO) questionnaire T-scores

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Registered

  5. Started